Global Expansion Translumina has recently expanded its geographical footprint by establishing a direct presence in the United Arab Emirates, providing new opportunities to introduce its cardiovascular devices to Middle Eastern markets and foster regional partnerships.

Strategic Acquisitions The company's acquisition of Blue Medical and Lamed demonstrates a proactive approach to enriching its product portfolio, particularly in drug-coated balloons and vascular surgery, creating avenues for cross-selling complementary devices within existing client bases.

Innovative Portfolio Launching advanced products like the Vivo Isar dual-drug coated stent signals a commitment to innovation, opening doors to engage hospitals and cardiology clinics seeking cutting-edge solutions for minimally invasive procedures.

Financial Growth With revenues between 50 and 100 million dollars supported by a funding pool of 70 million dollars, Translumina is financially positioned to invest in sales initiatives, expanding its presence in high-growth markets and targeting key healthcare providers.

Market Positioning As a fully integrated company with manufacturing capabilities in Germany and India, Translumina offers high-quality, competitive devices that can attract hospitals seeking reliable and innovative cardiovascular solutions, presenting significant upsell and new business opportunities.